BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Probe Scientific's Microeye® Technology Selected for Euros 5.2 Million EU In-Vivo Biomarker Monitoring Project


10/22/2012 9:47:02 AM

Coventry, UK, October 22, 2012: Probe Scientific Ltd, an emerging UK medical device developer, has announced that its breakthrough MicroEye in vivo sampling technology has been selected for a major new European biomarker research project.

The €5.2m project is designed to develop the use of MicroEye® with sensors for immunosuppressant drugs used to prevent rejection post transplantation. Researchers from a large number of European centres will take part.

Probe Scientific CEO Neil Smith commented: “Effectively tracking drug performance in intensive care situations such as post transplantation is critical. We believe MicroEye® sampling technology can provide the key to constructing robust monitoring systems in this case for cyclosporine and for other drugs in general. UsingMicroEye means that patient samples can now be collected in vivo and relevant drug metabolic data transmitted continuously,”

MicroEye is positioned in the body via a standard catheter, locking into place via a luer lock. The MicroEye® works when perfusate (e.g. saline) passes, through the device, which then continuously feeds plasma-like samples into a sensor for reading and data export. This microdialysis technology is proven and minimally invasive.

“We have already shown the efficacy and applicability of MicroEye® for continuous glucose monitoring and are also developing applications for other small molecules such as lactate. Currently we are inadvanced discussions for non-exclusive licences for a variety of applications and territories and will continue to sell further non-exclusive licences, “continues Smith.

For more information contact: Neil Smith, CEO, tel +44 (0)24 7632 3047,

e: neil.smith@probescientific.com

Media enquiries: Richard Hayhurst, tel + 44 (0)7711 821 527,

e: Richard@richard@richardhayhurstassociates.com

Probe Scientific focuses on innovative products to solve clinical problems and improve healthcare. The company has a substantial product pipeline based on its proprietary technologies, including MicroEye, and is seeking to commercialise this range to simultaneously benefit clinicians and the community in general. Probe Scientific Ltd is a private company, founded in 1998 and is based in the West Midlands, UK. Probe Scientific has grown steadily since its origins as a research organisation and has recently recruited experienced senior executives with a commercial focus.

www.probescientific.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES